Issue #92

New clinical breakthroughs, strengthened cash runways, and why these two stocks are leading the 2026 biotech rebound.

The biotech revolution isn’t being won by the loudest press releases or the flashiest laboratory demos—it’s being decided in the quiet, rigorous world of clinical trials where molecular precision meets human biology. As the sector shifts from broad, "one-size-fits-all" treatments to targeted, high-efficacy therapies, two frontiers matter more than anything else: reprogramming the immune system to fight chronic disease and erasing the genetic drivers of the world’s deadliest cancers.

This is where the biotech conversation shifts from speculation to clinical validation—and where the most durable, high-impact winners are emerging.

👉 One company is pioneering a novel oral therapy that could replace painful injections for millions of patients suffering from immune-mediated diseases.

👉 The other is systematically dismantling the RAS pathway, the "holy grail" of oncology that has frustrated drug developers for decades.

👉 Both have recently secured massive cash runways, validated their science with breakthrough data, and are positioned as the next major targets for "Big Pharma" acquisition.

In this edition, we break down the oral immunology breakthrough and the precision oncology powerhouse—and why these two stocks sit at the foundation of the next decade of biotech-driven growth.

Corvus Pharmaceuticals (NASDAQ: CRVS)

Corvus Pharmaceuticals (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company at the forefront of developing a new class of oral small molecule drugs designed to regulate the immune system. The company’s primary focus is on ITK inhibition, a novel approach that aims to treat both solid tumors and various immune-mediated diseases, such as atopic dermatitis (eczema) and T-cell lymphomas. By targeting the Interleukin-2-inducible T-cell kinase (ITK), Corvus seeks to provide more precise, oral alternatives to traditional injectable biologics.

Business Model and Revenue Streams 📦

As a clinical-stage biotech, Corvus operates on a high-stakes, research-heavy business model. The company does not currently have any FDA-approved products or recurring commercial revenue. Instead, its "business" is the development and de-risking of its proprietary drug candidates, with the goal of reaching commercialization or securing lucrative licensing deals.

• Pipeline Potential as Value: The company’s primary value resides in its lead candidate, soquelitinib. Revenue in the near-to-mid term is expected to come from potential milestone payments through strategic partnerships rather than direct product sales. For instance, Corvus maintains a partnership with Angel Pharmaceuticals in China, which provides a regional foothold for its portfolio.
• Capital-Intensive Operations: The business model relies heavily on the capital markets. Because the company spends millions on R&D without product sales, it maintains operations through periodic equity offerings—most recently a massive $201 million public offering in January 2026.

Macroeconomic policies, particularly interest rate trends and FDA regulatory environments, are the primary external drivers for CRVS. After a period of high interest rates that made funding difficult for small-cap biotechs, the 2025–2026 landscape has seen a "biotech rebound." Supportive FDA commentary on streamlining oncology treatments has improved investor sentiment. However, the company remains sensitive to inflation in clinical trial costs and the general "risk-off" sentiment that can affect speculative healthcare stocks.

Recent Performance and Corporate Developments 📈

Corvus has entered 2026 with significant momentum, largely driven by breakthrough clinical data and a strengthened balance sheet.

Q3 2025 and Recent Financial Highlights: 💰

• Improved Net Loss: For Q3 2025, Corvus reported a net loss of $10.2 million (or -$0.12 per share), a major improvement from the $40.2 million loss in the same period of 2024. This beat analyst expectations of -$0.14 per share.
• Cash Runway: As of late 2025, the company had $65.7 million in cash. However, following the January 2026 upsized offering, the company’s cash position has expanded significantly, likely extending its operational runway through 2027 or beyond.

Clinical Milestones and News: 🤝

The defining moment for CRVS recently was the January 20, 2026, announcement of Phase 1 data for soquelitinib in atopic dermatitis.

• Efficacy Breakthrough: Results showed that 75% of patients achieved a 75% improvement in their eczema (EASI 75) after eight weeks, comparing very favorably to existing blockbuster injectables.
• Pipeline Expansion: Corvus is now initiating a Phase 2 trial for atopic dermatitis and continues its registration-enabling Phase 3 trial for Peripheral T-cell Lymphoma (PTCL), with interim data expected in late 2026.

Profitability and Fair Value 🎯

Corvus is currently not profitable, which is typical for companies at this stage of drug development. Profitability depends entirely on the clinical success and eventual market approval of soquelitinib.

Regarding fair value, CRVS has seen a meteoric rise in early 2026, with the stock surging over 200% in a single month. Despite this, some valuation models suggest a stark contrast:

• DCF Perspective: Some analysts use Discounted Cash Flow models to estimate an intrinsic value of approximately $55 per share, suggesting the stock is still significantly undervalued if its drugs reach the market.
• Asset Perspective: Conversely, using a Price-to-Book (P/B) ratio, the stock looks "expensive" at over 20x, as the market is pricing in massive future expectations rather than current net assets.

Analyst Estimates and Ratings 📊

• Consensus Rating: The consensus among analysts is a "Strong Buy" or "Buy." In the last 30 days, several firms have reiterated their bullish stance following the eczema data.
• Price Targets: Following the recent rally, price targets have been revised upward. While the stock has traded near $17–$21 recently, Mizuho raised its target to $30, and Jefferies maintains a target as high as $42. The average 12-month consensus sits around $35.70, implying substantial upside remains.

Investor-Focused Takeaway: Is CRVS Right for Your Portfolio?

Corvus is a high-reward, high-risk play in the immunology and oncology space. The recent validation of their oral ITK inhibitor in a major market like atopic dermatitis has turned the company from a speculative "long shot" into a serious contender against established biologics.

What to Watch in the Near Term: 📈

• Phase 3 Interim Data: Watch for the late-2026 readout of the PTCL cancer trial; this is the company's fastest route to FDA approval.
• Phase 2 Initiation: The start of the larger atopic dermatitis study in early 2026 will be a key operational milestone.
• Partnership Rumors: Given the strong data, Corvus is a prime candidate for a partnership or acquisition by a "Big Pharma" player looking to add a potent oral immunology asset to their portfolio.

Erasca (NASDAQ: ERAS)

Erasca (NASDAQ: ERAS) is a clinical-stage precision oncology company with a bold mission embedded in its name: to "erase cancer." The company focuses exclusively on discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway—one of the most common and historically "undruggable" drivers of human cancer. Erasca’s strategy involves "shutting down" this pathway through both direct inhibition of RAS and targeting upstream/downstream signaling nodes.

Business Model and Revenue Streams 📦

Erasca operates as a high-growth, clinical-stage biotechnology firm. Similar to Corvus, its business model is centered on the long-term appreciation of its intellectual property rather than immediate product sales.

• RAS-Targeting Franchise: The core of Erasca's value lies in its proprietary candidates, specifically ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor). By developing "best-in-class" oral molecules that can target multiple mutations simultaneously, Erasca aims to capture a massive segment of the oncology market, including lung, colorectal, and pancreatic cancers.
• Strategic Prioritization: To maintain its financial health, Erasca recently shifted its model to focus strictly on its RAS-targeting assets. This included pausing enrollment for older programs like naporafenib to seek strategic partnerships, thereby converting potential liabilities into future licensing revenue opportunities.
• Capital and Macro Dynamics: The company is highly reliant on the equity markets for funding. Current macroeconomic conditions, characterized by a stabilizing interest rate environment in early 2026, have been favorable for Erasca. This "risk-on" sentiment allowed the company to execute a major capital raise, ensuring that macroeconomic fluctuations do not halt clinical progress in the near term.

Recent Performance and Corporate Developments 📈

Erasca has been exceptionally active in the first two months of 2026, transitioning from a purely speculative play to a company with tangible, early-stage clinical proof.

Recent Financial Performance: 💰

• Q3 2025 Results: Erasca reported a net loss of $30.6 million for the quarter ended September 30, 2025. This was a notable improvement from previous years, driven by a strategic reduction in R&D expenses as they narrowed their focus.
• Massive Capital Influx: In January 2026, Erasca closed a significantly upsized public offering of $258.8 million. This move was a masterstroke in financial planning, extending their projected cash runway into the second half of 2028.
• Earnings Stability: The company has consistently met analyst EPS estimates (around -$0.11 per share) throughout 2025, showing disciplined financial management despite the high costs of oncology trials.

Strategic News and Milestones: 🤝

• Clinical Momentum: On January 12, 2026, Erasca announced "meaningful clinical progress" for ERAS-0015. Early data showed confirmed partial responses in patients at low doses, signaling that the drug is both active and well-tolerated.
• Intellectual Property: In February 2026, the company secured a key U.S. patent for ERAS-4001, protecting its composition of matter through 2043. This adds a significant "moat" around their most promising KRAS asset.
• Executive Promotion: The promotion of Dr. Robert Shoemaker to Chief Scientific Officer in late 2025 underscores a period of internal stability as the company gears up for pivotal data readouts.

Profitability and Fair Value 🎯

Erasca is not yet profitable, with a current Return on Equity (ROE) of approximately -32%. However, for biotech investors, the "fair value" is often determined by the probability of success (PoS) of the pipeline rather than current earnings.

• Undervalued Growth: Following the recent capital raise and positive early data, several valuation models suggest the stock has been trading at a discount to its peers in the "pan-RAS" space.
• Market Positioning: With a market capitalization now exceeding $4 billion, Erasca is no longer a "micro-cap" secret. Its fair value is increasingly tied to its ability to compete with larger players like Revolution Medicines (RVMD). Analysts suggest that if Phase 1 data (expected H1 2026) continues to show high efficacy, the current price could be seen as a low entry point.

Analyst Estimates and Ratings 📊

• Consensus Rating: Erasca currently holds a "Buy" or "Moderate Buy" consensus. In the last 30 days, the stock has seen a surge in analyst attention following its 52-week highs.
• Price Targets: Analyst targets have been aggressive in early 2026. Mizuho recently initiated coverage with an "Outperform" rating and a $16.00 target. The average one-year price target was recently revised upward by over 60% to approximately $10.51, though the stock has already flirted with and surpassed these levels during the February rally.
• Bullish Sentiment: Institutional sentiment is high, with the put/call ratio sitting at a very bullish 0.15, suggesting that large traders are betting on further upside.

Investor-Focused Takeaway: Is ERAS Right for Your Portfolio?

Erasca represents a "pure play" on the next generation of cancer treatment. Unlike older drugs that target only one specific mutation, Erasca’s "pan-targeting" approach is designed to overcome the resistance that often makes cancer so deadly.

What to Watch in the Near Term: 📈

• H1 2026 Data Readout: The most significant catalyst is the upcoming monotherapy data for ERAS-0015. Positive topline results could trigger another leg up for the stock.
• H2 2026 Milestones: Watch for initial data from the BOREALIS-1 trial (ERAS-4001), which will determine if Erasca has a "double threat" in its portfolio.
• Strategic Partnerships: With a cash runway until 2028, Erasca is in a position of strength to negotiate a partnership for its non-core assets (like naporafenib), which could provide a non-dilutive cash infusion.

Recommendation:

Erasca (ERAS) is a compelling option for investors looking for exposure to the precision oncology revolution. While the stock has seen a rapid rise in early 2026, its massive cash cushion and validated pipeline make it a more stable "high-growth" bet than many of its clinical-stage peers.

Final Take: The Oral Immunology Breakthrough and the Precision Oncology Pipeline

The biotech rebound isn't about hope and headlines—it’s about clinical execution. And that requires two things: oral therapies that improve patient compliance and precision molecules that can finally target "undruggable" cancer pathways.

That’s where Corvus Pharmaceuticals (CRVS) and Erasca (ERAS) stand apart.

💊 Corvus Pharmaceuticals (CRVS) — The Future of Oral Immunology

✔ Breakthrough Phase 1 efficacy in atopic dermatitis (75% improvement)

✔ Lead asset soquelitinib targeting a massive market currently dominated by injectables

✔ Strong cash position following a $200M+ raise, fueling a pivotal Phase 3 oncology trial

➤ Best for: Investors looking for a high-upside immunology play with a "best-in-class" oral alternative to blockbuster biologics.

🧬 Erasca (ERAS) — The Architect of Pan-RAS Cancer Therapy

✔ Proprietary "molecular glue" and pan-KRAS inhibitors targeting 30% of all human cancers

✔ Massive $258M capital raise extending the operational runway through late 2028

✔ Strategic focus on the RAS/MAPK pathway, the "holy grail" of precision oncology

➤ Best for: Investors seeking exposure to the next generation of cancer treatment with deep intellectual property and a multi-year cash cushion.

Investor Insight

🧩 Want an oral immunology disruptor with massive market potential? → CRVS

⚙️ Want a precision oncology powerhouse with a fortress balance sheet? → ERAS

Bottom Line:

Biotech doesn't scale on theory—it scales on patient outcomes and trial data. Corvus is rewriting the script for immune-mediated diseases, while Erasca is building the toolkit to finally "erase" RAS-driven cancers.

As the sector moves from speculation to late-stage validation, CRVS and ERAS aren't just tickers—they’re the foundational assets of the 2026 biotech era.

​
Happy Trading
​— Team Premium Stock Alerts